Phénylacétate de sodium et benzoate de sodium : interactions médicamenteuses
Phénylacétate de sodium et benzoate de sodium (Ammonul) présente 49 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 0 de niveau majeur, 36 de niveau modéré, 13 de niveau mineur et 0 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.
Interactions d'après la notice
Interactions modérées (36)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (notice Phénylacétate de sodium et benzoate de sodium, Mises en garde et précautions)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (notice Phénylacétate de sodium et benzoate de sodium, Mises en garde et précautions)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (notice Phénylacétate de sodium et benzoate de sodium, Mises en garde et précautions)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (notice Phénylacétate de sodium et benzoate de sodium, Mises en garde et précautions)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (notice Phénylacétate de sodium et benzoate de sodium, Mises en garde et précautions)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (notice Phénylacétate de sodium et benzoate de sodium, Mises en garde et précautions)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (notice Phénylacétate de sodium et benzoate de sodium, Mises en garde et précautions)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (notice Phénylacétate de sodium et benzoate de sodium, Mises en garde et précautions)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (notice Phénylacétate de sodium et benzoate de sodium, Mises en garde et précautions)
- Phénylbutyrate de glycérolModérée
In a study of adult cancer patients, subjects received sodium phenylacetate administered as a 1-hour infusion twice daily at two dose levels of 125 and 150 mg/kg for a 2-week period. (notice Phénylbutyrate de glycérol, Mises en garde et précautions)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (notice Phénylacétate de sodium et benzoate de sodium, Mises en garde et précautions)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (notice Phénylacétate de sodium et benzoate de sodium, Mises en garde et précautions)
Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (notice Phénylacétate de sodium et benzoate de sodium, Mises en garde et précautions)
Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Mentions mineures (13)
There have been reports that valproic acid can induce hyperammonemia through inhibition of the synthesis of N-acetylglutamate, a co-factor for carbamyl phosphate synthetase. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
- ProbénécideMineure
Probenecid is known to inhibit the renal transport of many organic compounds, including aminohippuric acid, and may affect renal excretion of phenylacetylglutamine and hippurate. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
- Probénécide et colchicineMineure
Probenecid is known to inhibit the renal transport of many organic compounds, including aminohippuric acid, and may affect renal excretion of phenylacetylglutamine and hippurate. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)
Vérifiez Phénylacétate de sodium et benzoate de sodium avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.
Ouvrir dans le vérificateurCeci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.